Psilocybin Research for Addiction Treatment
Some of the most striking early results from psilocybin research concern its potential to help people overcome entrenched addictions. This page reviews the current scientific evidence for psilocybin-assisted treatment of smoking, alcohol use disorder, and other substance dependencies.
⚠️ Educational purposes only. Not medical or legal advice.
🔍 Considering psilocybin-assisted therapy for addiction? See our Therapist Directory for credentials to look for, screening questions, and how to find a qualified, addiction-informed practitioner.
Smoking Cessation Research
The most widely cited early study of psilocybin for addiction treatment is the smoking cessation pilot study conducted by Matthew Johnson and colleagues at Johns Hopkins University, published in 2014 in the journal Psychopharmacology. This open-label pilot enrolled 15 tobacco-dependent adults who had previously made multiple failed quit attempts. Participants received cognitive behavioral therapy (CBT) for smoking cessation combined with 2-3 psilocybin sessions at high doses (20 or 30 mg/70 kg) over a 15-week protocol. The biochemically verified 6-month abstinence rate was 80% — a figure that far exceeded the 15-35% rates typically seen with the most effective standard pharmacotherapies including varenicline (Chantix) and nicotine replacement therapy (NRT). At 12-month follow-up, 67% of participants remained abstinent, a level of sustained abstinence unprecedented in the smoking cessation literature.
A follow-up randomized controlled trial comparing psilocybin-facilitated smoking cessation with varenicline was published in 2023, providing more rigorous evidence. While this trial's full results were awaited at the time of writing, preliminary findings maintained the direction of the pilot study's results and demonstrated the feasibility of a controlled trial design in this indication. The Hopkins smoking cessation research established several key findings relevant to all addiction work: (1) the mystical experience quality of psilocybin sessions was the strongest predictor of abstinence outcomes — participants who reported more complete mystical experiences had better outcomes; (2) participants commonly described gaining a new perspective on their identity, specifically no longer identifying with the self-concept of "a smoker," which they found liberating and motivating; and (3) no significant safety concerns were identified in the carefully screened and monitored participant population.
Mechanism research within the smoking studies used functional MRI to examine changes in brain activity patterns associated with smoking cue reactivity. Participants showed reduced activation of brain circuits associated with craving in response to smoking-related images after psilocybin sessions, suggesting that the intervention may reduce cue-induced craving at a neural level. This is consistent with broader neuroimaging findings showing that psilocybin transiently disrupts rigid, habitual neural processing patterns — exactly the kind of entrenched pattern that characterizes addiction. The combination of this neural disruption with therapeutic preparation and integration appears to create a window of plasticity in which new behaviors and self-concepts can more readily replace the old addictive patterns.
Alcohol Use Disorder Studies
Alcohol use disorder (AUD) is one of the most prevalent and undertreated psychiatric conditions worldwide, with high rates of relapse even among those who access the best available treatments. The landmark trial of psilocybin for AUD was published in JAMA Psychiatry in 2022 by Michael Bogenschutz and colleagues at NYU. This randomized controlled trial enrolled 93 adults with AUD who received either two doses of psilocybin or two doses of diphenhydramine (antihistamine, active placebo) combined with motivational enhancement therapy. The psilocybin group showed significantly greater reductions in percentage of heavy drinking days — the primary outcome — compared to the placebo group, with 48% of the psilocybin group abstaining from alcohol altogether in the 32 weeks following the first medication session, compared to 24% in the placebo group. These are clinically meaningful differences in a population with severe, chronic AUD.
Earlier pilot work by Bogenschutz and colleagues (published in 2015) had established the feasibility and preliminary evidence for this approach in a smaller open-label study. That study found that the intensity of mystical experiences during psilocybin sessions significantly predicted reductions in drinking at 4-week and 3-month follow-ups. Participants described shifts in their motivation to drink, their sense of themselves as alcohol-dependent, and their relationship to what alcohol had provided for them — whether stress relief, social lubrication, or escape from emotional discomfort. The psilocybin experience appeared to create both a visceral confrontation with the costs of their drinking and a sense of expanded possibility that supported motivation for change.
Qualitative research accompanying the AUD studies has illuminated the subjective experience of change. Many participants described the psilocybin session as providing a profound shift in perspective — a bird's-eye view of their life that allowed them to see the role alcohol had played with unusual clarity and without the defensive distortions that typically accompany self-examination of addictive behavior. Some described mystical experiences that provided a sense of inherent self-worth and inner resource independent of alcohol — directly counteracting the shame and demoralization that often sustain addiction cycles. The combination of psychotherapy and psilocybin appears to create a therapeutic synergy in which the loosening of defensive rigidity during sessions makes the CBT and motivational work more effective.
Mechanisms of Action
Understanding why psilocybin might help with addiction requires examining both its pharmacological actions and its psychological mechanisms. At the pharmacological level, psilocybin's primary action is agonism of serotonin 2A (5-HT2A) receptors, which are densely expressed in prefrontal cortical circuits. This action produces the subjective altered state but also drives changes in synaptic plasticity — the brain's capacity to form and reorganize neural connections. Recent research has demonstrated that psilocybin, along with other psychedelics, promotes the rapid growth of dendritic spines (the physical substrate of neural connections) in prefrontal cortex and induces changes in gene expression associated with neuroplasticity. This suggests that psilocybin creates a period of enhanced neural plasticity — a window during which rigid, entrenched neural patterns (such as those underlying addiction) are more amenable to reorganization.
The disruption of default mode network (DMN) activity is a second key mechanism with particular relevance to addiction. The DMN is associated with self-referential processing, autobiographical memory, and narrative self-concept — in other words, the stories we tell about who we are. Addiction is deeply embedded in self-concept: the identity of being a smoker, a drinker, or a person who uses drugs becomes integrated into the self-narrative and is actively defended against change. Psilocybin's acute suppression of DMN activity, followed by a period of increased neural flexibility in the days after, appears to temporarily loosen the grip of this narrative self, creating an opportunity for genuine identity reorganization. This is experienced subjectively as the ability to see oneself and one's addictive behavior from a new perspective, often with greater compassion and less shame than ordinary self-reflection permits.
A third mechanism involves emotional memory reconsolidation and the reprocessing of unresolved psychological material that often underlies addictive behavior. Many people with substance use disorders have histories of trauma, attachment disruption, or chronic emotional pain that the addictive substance has functioned to manage or suppress. The psilocybin experience frequently brings unresolved emotional material to the surface in a context of heightened emotional openness and therapeutic support, enabling processing that conventional talk therapy alone may not achieve. This is one reason why the combination of psilocybin with psychotherapy — particularly trauma-informed approaches — is considered essential; the pharmacology opens a window, but skilled therapeutic support is what allows the window to be used productively rather than overwhelmingly.
Current Clinical Trials
As of 2026, a substantial number of clinical trials are examining psilocybin for various addiction indications. The landscape includes Phase II trials of psilocybin for cocaine use disorder, opioid use disorder, and cannabis use disorder at multiple academic medical centers. The University of Alabama at Birmingham, Imperial College London, Johns Hopkins, and NYU are among the leading academic institutions conducting active trial research. The FDA has granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression, and researchers hope that successful Phase III data in addiction indications may eventually support additional Breakthrough designations that would expedite regulatory review for these applications.
Opioid use disorder (OUD) research is at an earlier stage than smoking or alcohol research, partly because the complexity of opioid addiction — including the physical dependence, withdrawal, and overdose risk dimensions — requires more carefully designed protocols. Preliminary case reports and small pilot studies have examined psilocybin in individuals with OUD in the context of medication-assisted treatment (MAT) with buprenorphine or methadone, finding that concurrent MAT does not appear to substantially attenuate the psilocybin experience. A critical research question is whether psilocybin improves treatment engagement and retention in MAT programs, reduces craving and psychological distress in people on MAT, or helps with the transition off MAT in appropriate candidates. These questions are being explored in ongoing research.
The design of addiction clinical trials has evolved significantly based on early experience. Researchers have moved away from purely dose-finding and safety studies toward larger trials with active control conditions, meaningful clinical outcomes (abstinence, reduction in use days, quality of life), and careful attention to the therapeutic context — recognizing that the quality of the therapeutic relationship and the participant's preparation and integration experience are as important as the drug dose in determining outcomes. Several trials now incorporate digital tools to support integration work between sessions, measuring variables such as daily self-reported craving, mood, and substance use to track the trajectory of change more precisely than was possible in earlier studies. The field is moving rapidly and the trial landscape as of 2026 is substantially more sophisticated than that of five years prior.
Frequently Asked Questions
What did Matthew Johnson's smoking cessation study find?
The 2014 Johns Hopkins pilot study led by Matthew Johnson enrolled 15 tobacco-dependent adults with multiple failed prior quit attempts. Participants received cognitive behavioral therapy for smoking cessation combined with 2-3 high-dose psilocybin sessions over 15 weeks. The biochemically verified 6-month abstinence rate was 80% — dramatically higher than the 15-35% typical of the best standard pharmacotherapies. At 12-month follow-up, 67% remained abstinent. These results remained among the highest abstinence rates ever reported in the smoking cessation literature. The depth of the mystical experience during psilocybin sessions was the strongest predictor of abstinence outcomes, and participants commonly reported a fundamental shift in self-identity away from identifying as a smoker.
How do psilocybin quit rates compare to nicotine replacement therapy?
Standard nicotine replacement therapies (NRT — patches, gums, lozenges) achieve 6-month abstinence rates of approximately 10-20% compared to unassisted quit attempts. Varenicline (Chantix/Champix) achieves 20-30% 6-month abstinence in controlled trials and is generally considered the most effective pharmacotherapy for smoking cessation. The 80% 6-month abstinence rate in the Johns Hopkins psilocybin pilot, if replicated in larger controlled trials, would represent an unprecedented improvement over existing treatments. However, it is important to note that the Hopkins pilot was a small, open-label study with no control group, intensive therapeutic support, and highly selected participants — factors that may inflate the apparent response rate relative to what would be seen in broader clinical practice.
What were the outcomes in alcohol use disorder studies?
The 2022 JAMA Psychiatry RCT by Bogenschutz and colleagues found that two psilocybin sessions combined with motivational enhancement therapy produced significantly greater reductions in heavy drinking days compared to an active placebo (diphenhydramine) plus therapy condition. 48% of psilocybin participants were completely abstinent from alcohol in the 32 weeks following the first psilocybin session, compared to 24% in the placebo group. These abstinence rates are substantially higher than those achieved with the best available pharmacotherapies for AUD (naltrexone, acamprosate). The mystical experience quality during sessions again predicted outcomes, and qualitative data showed participants experienced fundamental shifts in their relationship to alcohol and their sense of personal identity.
Is there research on psilocybin for opioid addiction?
Research on psilocybin for opioid use disorder (OUD) is at an earlier stage than for tobacco or alcohol. Preliminary case reports, small case series, and pilot studies have examined feasibility and safety in individuals with OUD, often in the context of medication-assisted treatment (MAT) with buprenorphine or methadone. These early findings suggest the combination is feasible and does not produce dangerous interactions, but no large randomized trials specifically targeting OUD as the primary indication have been completed as of 2026. Ongoing studies are examining whether psilocybin can improve engagement with MAT, reduce craving, address comorbid depression and anxiety, and assist with treatment transitions. The complexity of opioid addiction — particularly overdose risk — requires particularly careful protocol design.
How might psilocybin help reset addictive habits?
Several complementary mechanisms have been proposed. Neuroplasticity effects — psilocybin promotes dendritic spine growth and enhances synaptic connectivity in prefrontal cortex — may create a window in which rigid, habitual neural patterns underlying addiction are more malleable. Default mode network disruption loosens the grip of the self-narrative ("I am an addict") that maintains addictive behavior and identity. The mystical-type experience frequently produces a sense of expanded perspective and personal significance that motivates change in a way that purely cognitive interventions cannot replicate. Emotional reprocessing during sessions addresses the unresolved psychological pain that many people use substances to manage. Integration therapy after sessions helps translate these acute changes into durable behavioral shifts. The combination of these mechanisms may explain why psilocybin appears to produce change that outlasts conventional approaches.
What is neuroplasticity and how does it relate to addiction treatment?
Neuroplasticity refers to the brain's capacity to form new neural connections, reorganize existing connections, and alter the strength of synaptic transmission — in other words, to physically change in response to experience. Addiction involves the entrenchment of specific neural circuits related to reward, craving, and habit — circuits that become increasingly dominant and resistant to modification through behavior change or standard pharmacotherapy alone. Psilocybin and other classical psychedelics have been shown to promote the rapid regrowth of dendritic spines (the physical structures that form synaptic connections) in prefrontal cortex and to enhance measures of neuroplasticity. This suggests that psilocybin may temporarily lower the barrier to neural reorganization — creating a therapeutic window in which the combination of powerful experience and skilled psychotherapy can more effectively overwrite entrenched addictive patterns.
Who conducts psilocybin addiction trials?
Major academic medical centers leading psilocybin addiction research include Johns Hopkins University (smoking, AUD, OUD), NYU Langone Center for Psychedelic Medicine (AUD, OUD), University of Alabama at Birmingham, University of New Mexico, Imperial College London, and the University of California system. In addition to academic centers, biotech companies including COMPASS Pathways, Usona Institute, and others are conducting clinical trials. MAPS (Multidisciplinary Association for Psychedelic Studies) focuses primarily on MDMA-assisted therapy but has contributed to broader psychedelic research infrastructure. ClinicalTrials.gov is the most comprehensive source for finding currently enrolling trials by substance type, location, and eligibility criteria.
Is psilocybin typically combined with CBT in addiction trials?
Yes. In the smoking cessation research at Hopkins, psilocybin was combined with a structured cognitive behavioral therapy (CBT) protocol for smoking cessation. In the AUD trial at NYU, psilocybin was combined with motivational enhancement therapy (MET), an evidence-based approach for alcohol and drug use disorders. Across addiction indications, psilocybin is consistently studied in combination with psychotherapy rather than as a standalone pharmacotherapy. Researchers consider the psychotherapy component essential — psilocybin creates a window of psychological openness and increased neuroplasticity, while the psychotherapy provides structure, safety, and a framework for translating the experience into durable change. The drug and therapy work synergistically, and neither alone is expected to produce the same outcome as the combination.
What are the relapse rates in psilocybin addiction studies?
Relapse data from psilocybin addiction studies vary by substance and follow-up period. In the Hopkins smoking study, 80% abstinence at 6 months dropped to 67% at 12 months, indicating some relapse over time but notably sustained abstinence for most participants. In the NYU AUD trial, the advantage of psilocybin over placebo in heavy drinking days was maintained through the 32-week observation period, but longer-term data were not yet published at the time of writing. Across studies, the pattern suggests that some participants experience sustained benefits while others show partial relapse — consistent with the general picture in addiction medicine, where most interventions produce a spectrum of outcomes. Integration of booster sessions or ongoing psychotherapy may be important for supporting long-term maintenance of gains.
Where can I find active clinical trials for psilocybin addiction research?
The most comprehensive and authoritative source for active clinical trials is ClinicalTrials.gov, the US National Institutes of Health's registry of publicly and privately funded clinical studies worldwide. Searching "psilocybin" filtered by condition (e.g., "tobacco use disorder," "alcohol use disorder," "opioid use disorder") and study status ("recruiting") will show currently enrolling trials. The Heffter Research Institute, MAPS, and the Usona Institute maintain websites with information about trials they fund or support. Academic medical center psychedelic research centers at Hopkins, NYU, UC San Francisco, and others publish information about their open studies. Eligibility criteria, locations, and contact information for each trial are provided in the ClinicalTrials.gov listings.